Vascular targeted therapies in oncology

被引:78
作者
Siemann, Dietmar W. [1 ]
Horsman, Michael R. [2 ]
机构
[1] Univ Florida, Dept Radiat Oncol, Gainesville, FL 32610 USA
[2] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark
关键词
Tumor vasculature; Vascular disrupting agents; Small-molecule vascular disrupting agents; Conventional anticancer therapies; Combined modality; Treatments; A-4 DISODIUM PHOSPHATE; COMBRETASTATIN A-4; ENDOTHELIAL-CELLS; TUMOR VASCULATURE; IN-VITRO; AGENT; RADIATION; ANGIOGENESIS; GROWTH; ENHANCEMENT;
D O I
10.1007/s00441-008-0646-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 47 条
[1]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[2]   MIGRATION AND PROLIFERATION OF ENDOTHELIAL CELLS IN PREFORMED AND NEWLY FORMED BLOOD-VESSELS DURING TUMOR ANGIOGENESIS [J].
AUSPRUNK, DH ;
FOLKMAN, J .
MICROVASCULAR RESEARCH, 1977, 14 (01) :53-65
[3]  
Blakey DC, 2002, CLIN CANCER RES, V8, P1974
[4]  
Bloemendal HJ, 1999, EUR J CLIN INVEST, V29, P802
[5]  
Chaplin DJ, 2006, CURR OPIN INVEST DR, V7, P522
[6]  
Chaplin DJ, 1999, BRIT J CANCER, V80, P57
[7]  
Davis PD, 2002, CANCER RES, V62, P7247
[8]  
Dowlati A, 2002, CANCER RES, V62, P3408
[9]  
Ellis L M, 2000, Oncologist, V5 Suppl 1, P11
[10]   Overview of angiogenesis: Biologic implications for antiangiogenic therapy [J].
Ellis, LM ;
Liu, WB ;
Ahmad, SA ;
Fan, F ;
Jung, YD ;
Shaheen, RM ;
Reinmuth, N .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :94-104